dc.contributor.author | Sevindik, Ömür | |
dc.contributor.author | Gemici, Aliihsan | |
dc.contributor.author | Mutlu, Yaşa Gül | |
dc.contributor.author | Balık Aydın, Berrin | |
dc.contributor.author | Çakır, Aslı | |
dc.date.accessioned | 2020-09-28T06:28:32Z | |
dc.date.available | 2020-09-28T06:28:32Z | |
dc.date.issued | 2020 | en_US |
dc.identifier.citation | Sevindik, Ö., Gemici, A., Mutlu, Y. G., Balık Aydın, B. ve Çakır, A. (2020). Rituximab-vemurafenib combination for the treatment of relapsed/Refractory hairy cell leukemia. Clinical Lymphoma, Myeloma & Leukemia içinde (S286-S286. ss.). | en_US |
dc.identifier.issn | 2152-2650 | |
dc.identifier.issn | 2152-2669 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/5870 | |
dc.description.abstract | Objective: The management of R/R-HCL is not standardized yet. Patients with HCL universally harbor BRAF mutations, which makes BRAF inhibitors a potential treatment approach. The effi cacy and safety of the BRAF inhibitor Vemurafenib were evaluated both as a single-agent option in two phase 2 trials and also combined with Rituximab in another phase 2 trial. Patients: We have decided to present the fi rst two consecutive patients who achieved a rapid and prolonged response, relapsing after treatment with purine analogues. The fi rst two patients who received a combination of R-V for R/R HCL from the records of our institutional CLPD registry were reported. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | CIG Media Group | en_US |
dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
dc.subject | Hairy Cell Leukemia | en_US |
dc.subject | HCL | en_US |
dc.subject | Combination Therapy | en_US |
dc.subject | Rituximab | en_US |
dc.subject | Vemurafenib | en_US |
dc.title | Rituximab-vemurafenib combination for the treatment of relapsed/Refractory hairy cell leukemia | en_US |
dc.type | conferenceObject | en_US |
dc.relation.ispartof | Clinical Lymphoma, Myeloma & Leukemia | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Tıbbi Patoloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-9636-4113 | en_US |
dc.authorid | 0000-0003-0128-6947 | en_US |
dc.identifier.volume | 20 | en_US |
dc.identifier.issue | Supplement: 1 | en_US |
dc.identifier.startpage | S286 | en_US |
dc.identifier.endpage | S286 | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.identifier.wosquality | Q3 | en_US |